MIC values (μg/ml) (Interpretation S/I/R) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | Species | AN | FOX | CIP | DOX | LZD | MXF | SXT | IMI | TGC | CLA after 5d | CLA after 14 d |
1 | Mabs | 16 (S) | 64 (I) | > 4 (R) | > 16 (R) | ≤ 1 (S) | 4 (R) | 4/76 (R) | 16 (I) | MIC = 1 | 0,06 (S) | 0,125 (S) |
2 | Mabs | 16 (S) | >128 (R) | > 4 (R) | > 16 (R) | 4 (S) | 2 (I) | > 8/152 (R) | 16 (I) | MIC = 0,5 | 0,06 (S) | > 16 (R) |
3 | Mabs | 16 (S) | 32 (I) | > 4 (R) | > 16 (R) | 4 (S) | > 8 (R) | 4/76 (R) | 16 (I) | MIC = 0,5 | 0,5 (S) | > 16 (R) |
4 | Mabs | 16 (S) | >128 (R) | > 4 (R) | > 16 (R) | 16 (I) | > 8 (R) | > 8/152 (R) | 16 (I) | MIC = 2 | 0,06 (S) | > 16 (R) |
5 | Mabs | 16 (S) | 64 (I) | > 4 (R) | > 16 (R) | 16 (I) | > 8 (R) | > 8/152 (R) | 16 (I) | MIC = 1 | 0,06 (S) | > 16 (R) |
6 | Mabs | 16 (S) | 64 (I) | > 4 (R) | > 16 (R) | 4 (S) | > 8 (R) | > 8/152 (R) | 16 (I) | MIC = 2 | 4 (I) | > 16 (R) |
7 | Mmas | - | - | - | - | - | - | - | - | - | - | - |
8 | Mmas | 16 (S) | >128 (R) | > 4 (R) | > 16 (R) | 16 (I) | 4 (R) | 4/76 (R) | 16 (I) | MIC = 0,25 | 0,06 (S) | 0,125 (S) |
9 | Mabs | 16 (S) | >128 (R) | > 4 (R) | > 16 (R) | 16 (I) | 4 (R) | 4/76 (R) | 16 (I) | MIC = 0,5 | 0,06 (S) | 0,125 (S) |
10 | Mmas | 16 (S) | 32 (I) | > 4 (R) | 1 (S) | 1 (S) | 2 (I) | 2/38 (S) | 16 (I) | MIC = 0,5 | 0,06 (S) | 0,06 (S) |
11 | Mbol | 4(S) | 32 (I) | > 4 (R) | > 16 (R) | 4 (S) | > 8 (R) | > 8/152 (R) | 16 (I) | MIC = 0.25 | 0.06 (S) | > 16 (R) |
12 | Mabs | 4 (S) | 33 (I) | > 4 (R) | > 16 (R) | 8 (S) | > 8 (R) | > 8/152 (R) | 16 (I) | MIC = 0.12 | 4 (I) | > 16 (R) |
Antimycobacterial agents | MIC breakpoints (μg/ml) | ||
---|---|---|---|
S | I | R | |
Amikacin | ≤ 16 | 32 | ≥ 64 |
Cefoxitin | ≤ 16 | 32-64 | ≥ 128 |
Doxycycline | ≤ 1 | 2-4 | ≥ 32 |
Ciprofloxacin | ≤ 1 | 2 | ≥ 4 |
Clarithromycin | ≤ 2 | 4 | ≥ 8 |
Linezolid | ≤ 8 | 16 | ≥ 32 |
Moxifloxacin | ≤ 1 | 2 | ≥ 4 |
Trimthoprim/sulfamethoazole | ≤ 2/38 | – | ≥ 4/76 |
Imipenem | ≤ 4 | 8-16 | ≥ 32 |
Tigecycline |
– | – | – |
No. of strain | Species | GenoType NTM-DR results | Phenotypic results of susceptibility to amikacin | |
---|---|---|---|---|
Type of bands (WT or mutation) | Molecular mechanisms of resistance (Yes/No) | |||
1 | Mabs | No | (S) | |
2 | Mabs | No | (S) | |
3 | Mabs | No | (S) | |
4 | Mabs | No | (S) | |
5 | Mabs | No | (S) | |
6 | Mabs | No | (S) | |
7 | Mmas | No | nt | |
8 | Mmas | No | (S) | |
9 | Mabs | Yes | (S) | |
10 | Mmas | No | (S) | |
11 | Mb ol | No | (S) | |
12 | Mabs | No | (S) |
Strip 1 | – a clinical strain of |
Strips 2-6, 10, 12 - | –clinical strains of |
Strips 7, 9 | – clinical strains of |
Strips 8 | – clinical strains of |
Strip 11 | – clinical strains of |
Discernible phenotypic pattern resistance | Target nucleic acid sequence | Nascent mutation band | Mutation |
---|---|---|---|
Macrolides | 2058–2059 | A2058C | |
A2058G | |||
– | A2058T | ||
A2059C | |||
A2059T | |||
Aminoglycosides | 1406–1409 | A1408G | |
– | T1406A | ||
– | C1409T |
No. | Species | AN | Interpretation |
CLA after 5 days of incubation | Interpretation |
CLA after 14 days of incubation | Interpretation |
---|---|---|---|---|---|---|---|
1 | Mabs | 16 | (S) | 0.06 | (S) | 0,5 | (S) |
2 | Mabs | 8 | (S) | 0.06 | (S) | > 64 | (R) |
3 | Mabs | 16 | (S) | 0.06 | (S) | = 32 | (R) |
4 | Mabs | 16 | (S) | 0.06 | (S) | = 32 | (R) |
5 | Mabs | 16 | (S) | 0.06 | (S) | = 32 | (R) |
6 | Mabs | 16 | (S) | 0.06 | (S) | = 32 | (R) |
7 | Mmas | – | – | – | – | – | – |
8 | Mmas | 16 | (S) | 0.06 | (S) | = 0.125 | (S) |
9 | Mabs | 16 | (S) | 0.06 | (S) | = 0.125 | (S) |
10 | Mmas | 16 | (S) | 0.06 | (S) | = 0.06 | (S) |
11 | Mbol | 0.5 | (S) | 0.06 | (S) | > 64 | (R) |
12 | Mabs | 0.250 | (S) | 4 | (R) | = 16 | (R) |
No. of strain | Species | GenoType NTM-DR results | Phenotypic results of susceptibility to clarithromycin | |
---|---|---|---|---|
Type of bands (WT or mutation) | Molecular mechanisms of resistance (Yes/No) | |||
1 | Mabs | No | (S) | |
2 | Mabs | Yes | (R) | |
3 | Mabs | Yes | (R) | |
4 | Mabs | Yes | (R) | |
5 | Mabs | Yes | (R) | |
6 | Mmas | Yes | (R) | |
7 | Mmas | No | nt | |
8 | Mmas | No | (S) | |
9 | Mabs | Yes | (S) | |
10 | Mb ol | No | (S) | |
11 | Mabs | Yes | (R) | |
12 | Mabs | Yes | (R) |